Diverse Voices: Intersectionality and the Health of Women - March 27, 2025
Date and Time
– March 27, 2025, 4:00 PM EDTVirtual Only.
The March 2025 session of Diverse Voices: Intersectionality and the Health of Women is titled “Utilizing Vaginal Specimens to Identify Cancer.” The session will feature presentations by Deborah Watkins Bruner, R.N., Ph.D., FAAN, and Megan Clarke, Ph.D., M.H.S.
Dr. Bruner will present on “Associations Among HPV Persistence, the Vaginal Microbiome, and Cervical Cancer Recurrence” and Dr. Clarke will present on “Understanding the Acceptability and Feasibility of Vaginal Tampon Sampling for Detection of Endometrial and Ovarian Cancers.”
Registration information coming soon.
 | Deborah Watkins Bruner, R.N., Ph.D., FAAN Senior Vice President for Research Emory University “Associations Among HPV Persistence, the Vaginal Microbiome, and Cervical Cancer Recurrence" Dr. Bruner is an internationally renowned cancer researcher and clinical trialist with a focus on patient reported outcomes and symptom management. Her most current research is focused on the role of the human microbiome in carcinogenesis and cancer treatment outcomes for women with gynecologic cancers. She will share her preliminary findings on bacterial species in the vaginal microbiome related to human papillomavirus (HPV) persistence post cervical cancer treatments and recurrence. |
 | Megan Clarke, Ph.D., M.H.S. Director of Global Epidemiology AbbVie “Understanding the Acceptability and Feasibility of Vaginal Tampon Sampling for the Detection of Endometrial and Ovarian Cancers” Dr. Clarke’s research has focused on the etiology, prevention, and early detection of anogenital and endometrial cancers, with a strong emphasis on cancer disparities. Her talk will focus on the Discovery and Evaluation of Tests for Endometrial and ovarian Cancer in Tampons (DETECT) study. DETECT is a case control study, designed by Dr. Clarke and her clinical colleagues in the Division of Gynecologic Oncology at the University of Alabama at Birmingham, to evaluate the performance of biomarkers that are measured from self-collected vaginal tampons for the detection of endometrial and ovarian cancer. |
Sign language interpreting services are available upon request. Individuals who need interpreting services and/or other reasonable accommodations to participate in this event should contact Liz Schott. Requests should be made at least five business days in advance.